KEY TAKEAWAYS The phase 1 trial aimed to investigate the preliminary safety and antitumor activity of ASP3082 monotherapy in patients with KRAS G12D-mutant advanced solid tumors. The primary endpoints were to determine the DLTs and AEs. Researchers noted ASP3082’s...